295 related articles for article (PubMed ID: 9552174)
21. The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms.
Deep P; Kuwabara H; Gjedde A; Cumming P
J Neurosci Methods; 1997 Dec; 78(1-2):157-68. PubMed ID: 9497012
[TBL] [Abstract][Full Text] [Related]
22. [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine.
Firnau G; Garnett ES; Chirakal R; Sood S; Nahmias C; Schrobilgen G
Int J Rad Appl Instrum A; 1986; 37(8):669-75. PubMed ID: 3021668
[TBL] [Abstract][Full Text] [Related]
23. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
24. Loss of metabolites from monkey striatum during PET with FDOPA.
Cumming P; Munk OL; Doudet D
Synapse; 2001 Sep; 41(3):212-8. PubMed ID: 11391782
[TBL] [Abstract][Full Text] [Related]
25. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
26. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
[TBL] [Abstract][Full Text] [Related]
27. Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.
Reith J; Dyve S; Kuwabara H; Guttman M; Diksic M; Gjedde A
J Cereb Blood Flow Metab; 1990 Sep; 10(5):707-19. PubMed ID: 2117017
[TBL] [Abstract][Full Text] [Related]
28. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
[TBL] [Abstract][Full Text] [Related]
29. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
31. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
32. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
Holden JE; Doudet D; Endres CJ; Chan GL; Morrison KS; Vingerhoets FJ; Snow BJ; Pate BD; Sossi V; Buckley KR; Ruth TJ
J Nucl Med; 1997 Oct; 38(10):1568-74. PubMed ID: 9379194
[TBL] [Abstract][Full Text] [Related]
33. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.
Hefti F; Melamed E; Wurtman RJ
J Neural Transm Suppl; 1980; (16):95-101. PubMed ID: 6776238
[TBL] [Abstract][Full Text] [Related]
34. [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis.
Cumming P; Ase A; Kuwabara H; Gjedde A
J Cereb Blood Flow Metab; 1998 May; 18(5):491-9. PubMed ID: 9591841
[TBL] [Abstract][Full Text] [Related]
35. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
Hartvig P; Agren H; Reibring L; Tedroff J; Bjurling P; Kihlberg T; Långström B
J Neural Transm Gen Sect; 1991; 86(1):25-41. PubMed ID: 1751027
[TBL] [Abstract][Full Text] [Related]
36. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder.
Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Cohen RM
Am J Psychiatry; 1999 Aug; 156(8):1209-15. PubMed ID: 10450262
[TBL] [Abstract][Full Text] [Related]
37. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
[TBL] [Abstract][Full Text] [Related]
38. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
Opacka-Juffry J; Brooks DJ
Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
[TBL] [Abstract][Full Text] [Related]
39. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
[TBL] [Abstract][Full Text] [Related]
40. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines.
Gordonsmith RH; Raxworthy MJ; Gulliver PA
Biochem Pharmacol; 1982 Feb; 31(3):433-7. PubMed ID: 6803810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
